Cortellini et al. retrospectively reviewed the impact of muscle quality on PFS in association with PD‐1/PD‐L1 inhibitor use in a mixed cancer population comprising 46 patients with advanced NSCLC and 54 patients with other advanced cancers including renal cell carcinoma and melanoma.14 The gene discussed is PDCD1; the disease is hereditary clear cell renal cell carcinoma.